about
Spontaneous and pronase-induced HER2 truncation increases the trastuzumab binding capacity of breast cancer tissues and cell linesPirin delocalization in melanoma progression identified by high content immuno-detection based approachesLoss of negative regulation by Numb over Notch is relevant to human breast carcinogenesisHER2 in situ hybridization in breast cancer: clinical implications of polysomy 17 and genetic heterogeneityAlterations of the Notch pathway in lung cancer.Reciprocal repression between P53 and TCTPHER2 testing in gastric cancer: a practical approachNUMB controls p53 tumour suppressor activityBiological and molecular heterogeneity of breast cancers correlates with their cancer stem cell contentTamoxifen for the prevention of breast cancer: late results of the Italian Randomized Tamoxifen Prevention Trial among women with hysterectomyHow reliable is Ki-67 immunohistochemistry in grade 2 breast carcinomas? A QA study of the Swiss Working Group of Breast- and GynecopathologistsIdentification of new hematopoietic cell subsets with a polyclonal antibody library specific for neglected proteinsSensitivity of imaging for multifocal-multicentric breast carcinoma.A RAB5/RAB4 recycling circuitry induces a proteolytic invasive program and promotes tumor dissemination.Adjuvant Lapatinib and Trastuzumab for Early Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: Results From the Randomized Phase III Adjuvant Lapatinib and/or Trastuzumab Treatment Optimization Trial.Impact of updated HER2 testing guidelines in breast cancer--re-evaluation of HERA trial fluorescence in situ hybridization data.Vinorelbine-based salvage therapy in HER2-positive metastatic breast cancer patients progressing during trastuzumab-containing regimens: a retrospective study.The Gene expression Grade Index: a potential predictor of relapse for endocrine-treated breast cancer patients in the BIG 1-98 trial.Trastuzumab with either docetaxel or vinorelbine as first-line treatment for patients with HER2-positive advanced breast cancer: a retrospective comparison.An international reproducibility study validating quantitative determination of ERBB2, ESR1, PGR, and MKI67 mRNA in breast cancer using MammaTyper®Central pathology laboratory review of HER2 and ER in early breast cancer: an ALTTO trial [BIG 2-06/NCCTG N063D (Alliance)] ring study.Molecular risk assessment of BIG 1-98 participants by expression profiling using RNA from archival tissue.Immunohistochemical Performance of Estrogen and Progesterone Receptor Antibodies on the Dako Omnis Staining Platform: Evaluation in Multicenter Studies.Prognostic interaction between expression of p53 and estrogen receptor in patients with node-negative breast cancer: results from IBCSG Trials VIII and IXAn atlas of altered expression of deubiquitinating enzymes in human cancerThe AURORA pilot study for molecular screening of patients with advanced breast cancer-a study of the breast international groupRecommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update.Proposed new clinicopathological surrogate definitions of luminal A and luminal B (HER2-negative) intrinsic breast cancer subtypesAnalytical validation of a standardized scoring protocol for Ki67: phase 3 of an international multicenter collaboration.Frequent alterations in the expression of serine/threonine kinases in human cancers.Combined small-cell carcinoma of the lung with quadripartite differentiation of epithelial, neuroendocrine, skeletal muscle, and myofibroblastic type.Adjuvant exemestane with ovarian suppression in premenopausal breast cancer.Gene status in HER2 equivocal breast carcinomas: impact of distinct recommendations and contribution of a polymerase chain reaction-based method.70-Gene Signature as an Aid to Treatment Decisions in Early-Stage Breast Cancer.Validation and clinical utility of a 70-gene prognostic signature for women with node-negative breast cancer.Pirin inhibits cellular senescence in melanocytic cells.Adjuvant ovarian suppression in premenopausal breast cancer.RANK-ligand (RANKL) expression in young breast cancer patients and during pregnancy.Assessment of Ki67 in breast cancer: recommendations from the International Ki67 in Breast Cancer working groupEstrogen and HER-2 receptor discordance between primary breast cancer and metastasis.
P50
Q24293655-37F2C41F-B5C7-4D38-AB97-84498FB45650Q24296655-EF2204AF-36BE-4597-941D-A6572C3AC22EQ24676117-6F888324-C570-47B1-804A-4CADA69CD7D1Q27006811-04F6F158-6B5B-42A8-91FB-FF9CFAB180F1Q27851544-57E5E10E-D054-4B8D-BDF3-BFD4E12F8DC0Q28255116-5EA9CA11-F920-475C-A442-47EAA4EEC365Q28256814-C82DA3E7-4066-4878-AF4E-4A83F88F3219Q28263413-045AAAA1-5458-4365-B25E-4C89AE289B64Q28270471-CF86C36B-F999-4108-8AF8-8C0359874A18Q28300092-EF1D069C-E33F-4A5C-AF3A-E7C3ED39E12DQ28729183-1C6E5920-4B78-49AD-8CE9-3FB0E14C4B47Q28730752-63412BE8-79EE-459C-9164-479E784130E0Q30492873-E157E611-CF8A-4D29-B6ED-EB8E3DA7E9F5Q30584664-6F26BC6A-C294-47C5-844B-05E87104479FQ30758991-9955216E-B6A6-4A1F-B2E5-DA95D9D83375Q30996906-70EF3A5F-B93C-4C3E-B2E3-06170C9339D9Q33354783-C43B3EDF-8590-4AF5-A00A-2F89ABA2DBE6Q33477635-0D8149B1-8EA2-4BF7-B456-18B10CCED700Q33528162-E5B5336E-635D-4205-9535-12BE1B8D7503Q33660598-7693DEB3-1064-46CA-B89F-004B01EE1D9BQ33688726-5FD15D3C-9A62-475E-A3A8-D943CF86CBF0Q33692020-D5046A71-CD27-4AD6-98DC-287072EA93CAQ33736780-77E47A91-3334-478E-B251-51306D2BD735Q33739357-3F44D335-6FB7-4765-8702-68FBD5ABC65BQ33808690-2ECF640D-058D-409B-B4BD-651CE5222141Q33854251-9E5B6C6A-1C56-4E4E-92C4-1149939C2C9FQ33862786-D65F0CEC-449E-45BA-AB6B-C64CFEB981AFQ33892778-41B96CD3-BACA-4A65-91E8-31D545164BF3Q33915010-93966224-9ED4-4F46-B08A-80C055224356Q33998589-80124AE0-2A5C-4CD4-8AEC-65265FDABB4DQ34157789-029995BC-F145-47D2-80E8-BED353418022Q34245992-3CBF6549-10EF-4CE8-9236-EF0BC14B366CQ34458036-26F727F1-073E-465C-9F7A-E939A41C94A6Q34538363-4D1B9C77-09FC-473E-9F5A-685E645D948EQ34563697-7BCC7649-E241-4B4F-8E60-D05DCA356C6BQ34838382-E120499B-B070-4749-A7CE-4A2833D4A7E2Q35124558-D5B6A994-16A2-41FB-AC54-8988D15489A6Q35218182-3F9D39C9-8F34-450C-8D2A-1E2434291C7AQ35552069-869BB5EB-FB17-48E5-B386-4A318289222BQ35583809-EF8C9F38-8049-4D18-9464-6399E7B72365
P50
name
Giuseppe Viale
@en
Giuseppe Viale
@nl
type
label
Giuseppe Viale
@en
Giuseppe Viale
@nl
prefLabel
Giuseppe Viale
@en
Giuseppe Viale
@nl